Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBT: 2020-2024

Historic EBT for Krystal Biotech (KRYS) over the last 5 years, with Dec 2024 value amounting to $95.4 million.

  • Krystal Biotech's EBT rose 61.13% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.9 million, marking a year-over-year increase of 225.68%. This contributed to the annual value of $95.4 million for FY2024, which is 639.37% up from last year.
  • According to the latest figures from FY2024, Krystal Biotech's EBT is $95.4 million, which was up 639.37% from $12.9 million recorded in FY2023.
  • Krystal Biotech's EBT's 5-year high stood at $95.4 million during FY2024, with a 5-year trough of -$140.0 million in FY2022.
  • Its 3-year average for EBT is -$10.6 million, with a median of $12.9 million in 2023.
  • As far as peak fluctuations go, Krystal Biotech's EBT plummeted by 116.28% in 2021, and later surged by 639.37% in 2024.
  • Over the past 5 years, Krystal Biotech's EBT (Yearly) stood at -$32.2 million in 2020, then crashed by 116.28% to -$69.6 million in 2021, then tumbled by 101.20% to -$140.0 million in 2022, then skyrocketed by 109.21% to $12.9 million in 2023, then skyrocketed by 639.37% to $95.4 million in 2024.